Generic Suprenza Availability
SUPRENZA (phentermine hydrochloride - tablet, orally disintegrating;oral)
Manufacturer: CITIUS PHARMS
Approval date: June 13, 2011
Strength(s): 15MG, 30MG
Manufacturer: CITIUS PHARMS
Approval date: March 27, 2012
Strength(s): 37.5MG [RLD]
Has a generic version of Suprenza been approved?
No. There is currently no therapeutically equivalent version of Suprenza available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Suprenza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets and compositions obtained thereby
Issued: November 21, 2000
Inventor(s): Bonadeo; Daniele & Ciccarello; Franco & Pagano; Aberto
Assignee(s): Elan Pharma International Limited
A process for making a granulate composition suitable to the preparation of an oral solid form that can disintegrate rapidly inside the buccal cavity is provided as well as the granulate compositions and obtained.Patent expiration dates:
- July 23, 2018✓✓
- July 23, 2018✓
- July 23, 2018
Orally disintegrating tablets with speckled appearance
Issued: May 14, 2013
Assignee(s): Alpex Pharma SA
Orally disintegrating tablets containing colored granules of a water-soluble sugar which give them a speckled appearance are described. The orally disintegrating tablets with speckled appearance are readily and easy identifiable by physicians, nurses and patients.Patent expiration dates:
- March 14, 2029✓
- March 14, 2029
More about Suprenza (phentermine)
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|